Delia Mezzanzanica

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7020170/publications.pdf

Version: 2024-02-01

101 papers	3,903 citations	117453 34 h-index	133063 59 g-index
102 all docs	102 docs citations	102 times ranked	5897 citing authors

#	Article	IF	Citations
1	Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity. International Journal of Cancer, 1987, 39, 297-303.	2.3	284
2	Alterations of Choline Phospholipid Metabolism in Ovarian Tumor Progression. Cancer Research, 2005, 65, 9369-9376.	0.4	258
3	Activation of Phosphatidylcholine Cycle Enzymes in Human Epithelial Ovarian Cancer Cells. Cancer Research, 2010, 70, 2126-2135.	0.4	196
4	Cellular FLICE-inhibitory protein (c-FLIP) signalling: A key regulator of receptor-mediated apoptosis in physiologic context and in cancer. International Journal of Biochemistry and Cell Biology, 2010, 42, 210-213.	1.2	129
5	Gynecologic Cancer InterGroup (GCIG) Consensus Review for Clear Cell Carcinoma of the Ovary. International Journal of Gynecological Cancer, 2014, 24, S20-S25.	1.2	116
6	IL-27 induces the expression of IDO and PD-L1 in human cancer cells. Oncotarget, 2015, 6, 43267-43280.	0.8	115
7	Augmentation of Response to Chemotherapy by microRNA-506 Through Regulation of RAD51 in Serous Ovarian Cancers. Journal of the National Cancer Institute, 2015, 107, .	3.0	102
8	Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study. Lancet Oncology, The, 2016, 17, 1137-1146.	5.1	97
9	The ALCAM Shedding by the Metalloprotease ADAM17/TACE Is Involved in Motility of Ovarian Carcinoma Cells. Molecular Cancer Research, 2007, 5, 1246-1253.	1.5	95
10	<scp>MiR</scp>â€506 inhibits multiple targets in the epithelialâ€toâ€mesenchymal transition network and is associated with good prognosis in epithelial ovarian cancer. Journal of Pathology, 2015, 235, 25-36.	2.1	94
11	Phosphatidylcholine-Specific Phospholipase C Activation in Epithelial Ovarian Cancer Cells. Cancer Research, 2008, 68, 6541-6549.	0.4	86
12	Subcellular Localization of Activated Leukocyte Cell Adhesion Molecule Is a Molecular Predictor of Survival in Ovarian Carcinoma Patients. Clinical Cancer Research, 2008, 14, 1726-1733.	3.2	83
13	M-CAM expression as marker of poor prognosis in epithelial ovarian cancer. International Journal of Cancer, 2006, 119, 1920-1926.	2.3	78
14	Gene expression profiling of advanced ovarian cancer: characterization of a molecular signature involving fibroblast growth factor 2. Oncogene, 2004, 23, 8171-8183.	2.6	75
15	Gynecologic Cancer InterGroup (GCIG) Consensus Review for Ovarian Tumors of Low Malignant Potential (Borderline Ovarian Tumors). International Journal of Gynecological Cancer, 2014, 24, S5-S8.	1.2	74
16	Gynecologic Cancer InterGroup (GCIG) Consensus Review for Ovarian Sex Cord Stromal Tumors. International Journal of Gynecological Cancer, 2014, 24, S42-S47.	1.2	74
17	Human ovarian carcinoma lysis by cytotoxic t cells targeted by bispecific monoclonal antibodies: Analysis of the antibody components. International Journal of Cancer, 1988, 41, 609-615.	2.3	70
18	Redirected Activity of Human Antitumor Chimeric Immune Receptors is Governed by Antigen and Receptor Expression Levels and Affinity of Interaction. Journal of Immunotherapy, 2007, 30, 684-693.	1.2	70

#	Article	IF	Citations
19	Reversion of transformed phenotype in ovarian cancer cells by intracellular expression of anti folate receptor antibodies. Gene Therapy, 2003, 10, 1018-1025.	2.3	68
20	Role of microRNAs in ovarian cancer pathogenesis and potential clinical implications. International Journal of Biochemistry and Cell Biology, 2010, 42, 1262-1272.	1.2	63
21	CDK6 protects epithelial ovarian cancer from platinumâ€induced death via FOXO3 regulation. EMBO Molecular Medicine, 2017, 9, 1415-1433.	3.3	61
22	Identification of a chrXq27.3 microRNA cluster associated with early relapse in advanced stage ovarian cancer patients. Oncotarget, 2011, 2, 1265-1278.	0.8	61
23	CD95-Mediated Apoptosis Is Impaired at Receptor Level by Cellular FLICE-Inhibitory Protein (Long Form) in Wild-Type p53 Human Ovarian Carcinoma. Clinical Cancer Research, 2004, 10, 5202-5214.	3.2	52
24	T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2. Clinical and Experimental Metastasis, 2015, 32, 29-38.	1.7	51
25	Stathmin regulates mutant p53 stability and transcriptional activity in ovarian cancer. EMBO Molecular Medicine, 2013, 5, 707-722.	3.3	49
26	Choline kinase-alpha by regulating cell aggressiveness and drug sensitivity is a potential druggable target for ovarian cancer. British Journal of Cancer, 2014, 110, 330-340.	2.9	45
27	Clinicopathological Impact of ABCC1/MRP1 and ABCC4/MRP4 in Epithelial Ovarian Carcinoma. BioMed Research International, 2013, 2013, 1-7.	0.9	43
28	Bispecific Antibody Targeted T Cell Therapy of Ovarian Cancer: Clinical Results and Future Directions. Stem Cells and Development, 1995, 4, 423-427.	1.0	42
29	Expression of interleukin-18 in human ovarian carcinoma and normal ovarian epithelium: Evidence for defective processing in tumor cells. International Journal of Cancer, 2002, 98, 873-878.	2.3	42
30	Activation of mononuclear cells to be used for hybrid monoclonal antibody-induced lysis of human ovarian carcinoma cells. International Journal of Cancer, 1988, 42, 455-459.	2.3	41
31	The IL-18 Antagonist IL-18â€“Binding Protein Is Produced in the Human Ovarian Cancer Microenvironment. Clinical Cancer Research, 2013, 19, 4611-4620.	3.2	40
32	Choline Metabolism Alteration: A Focus on Ovarian Cancer. Frontiers in Oncology, 2016, 6, 153.	1.3	40
33	Activated leukocyte cell adhesion molecule soluble form: a potential biomarker of epithelial ovarian cancer is increased in type II tumors. International Journal of Cancer, 2013, 132, 2597-2605.	2.3	39
34	The Aspergillus toxin restrictocin is a suitable cytotoxic agent for generation of immunoconjugates with monoclonal antibodies directed against human carcinoma cells. FEBS Journal, 1989, 178, 795-802.	0.2	38
35	Complement Activated by Chimeric Antiâ€“Folate Receptor Antibodies Is an Efficient Effector System to Control Ovarian Carcinoma. Cancer Research, 2006, 66, 3876-3883.	0.4	36
36	Redirection of T-cell effector functions for cancer therapy: bispecific antibodies and chimeric antigen receptors. Future Oncology, 2013, 9, 527-539.	1.1	35

#	Article	IF	Citations
37	Ovarian cancer: a molecularly insidious disease. Chinese Journal of Cancer, 2015, 34, 1-3.	4.9	34
38	Immunoconjugate generation between the ribosome inactivating protein restrictocin and an anti-human breast carcinoma MAB. Cancer Immunology, Immunotherapy, 1988, 26, 114-20.	2.0	33
39	Change in Binding Reactivity of an Anti-Tumor Monoclonal Antibody After the Introduction of 2-Pyridyl Disulphide Groups. Hybridoma, 1986, 5, 1-8.	0.9	32
40	ROLE OF CYTOKINES IN CANCER CACHEXIA IN A MURINE MODEL OF INTRACEREBRAL INJECTION OF HUMAN TUMOURS. Cytokine, 2001, 15, 27-38.	1.4	32
41	Characterisation of in vivo ovarian cancer models by quantitative ¹H magnetic resonance spectroscopy and diffusionâ€weighted imaging. NMR in Biomedicine, 2012, 25, 632-642.	1.6	30
42	One-Carbon Metabolism: Biological Players in Epithelial Ovarian Cancer. International Journal of Molecular Sciences, 2018, 19, 2092.	1.8	27
43	Highly efficient redirected anti-tumor activity of human lymphocytes transduced with a completely human chimeric immune receptor. Journal of Gene Medicine, 2005, 7, 158-170.	1.4	26
44	Epigenetic Control of Autophagy by MicroRNAs in Ovarian Cancer. BioMed Research International, 2014, 2014, 1-11.	0.9	26
45	Key nodes of a microRNA network associated with the integrated mesenchymal subtype of high-grade serous ovarian cancer. Chinese Journal of Cancer, 2015, 34, 28-40.	4.9	26
46	A novel isoform of pro-interleukin-18 expressed in ovarian tumors is resistant to caspase-1 and -4 processing. Oncogene, 2004, 23, 7552-7560.	2.6	25
47	Interleukin (IL)â€18, a biomarker of human ovarian carcinoma, is predominantly released as biologically inactive precursor. International Journal of Cancer, 2011, 129, 1116-1125.	2.3	25
48	Simultaneous E-cadherin and PLEKHA7 expression negatively affects E-cadherin/EGFR mediated ovarian cancer cell growth. Journal of Experimental and Clinical Cancer Research, 2018, 37, 146.	3.5	25
49	High-throughput assessment of the antibody profile in ovarian cancer ascitic fluids. OncoImmunology, 2019, 8, e1614856.	2.1	25
50	Monitoring response to cytostatic cisplatin in a HER2(+) ovary cancer model by MRI and in vitro and in vivo MR spectroscopy. British Journal of Cancer, 2014, 110, 625-635.	2.9	24
51	UQCRH gene encoding mitochondrial Hinge protein is interrupted by a translocation in a soft-tissue sarcoma and epigenetically inactivated in some cancer cell lines. Oncogene, 2003, 22, 4586-4593.	2.6	23
52	Sensitization of p53-mutated epithelial ovarian cancer to CD95-mediated apoptosis is synergistically induced by cisplatin pretreatment. Molecular Cancer Therapeutics, 2007, 6, 762-772.	1.9	21
53	Increased Sensitivity to Chemotherapy Induced by CpG-ODN Treatment Is Mediated by microRNA Modulation. PLoS ONE, 2013, 8, e58849.	1.1	21
54	Use of combination of monoclonal antibodies directed against three distinct epitopes of a tumor-associated antigen: Analysis of cell binding and internalization. International Journal of Cancer, 1991, 48, 284-290.	2.3	20

#	Article	IF	Citations
55	Enhancing ovarian cancer conventional chemotherapy through the combination with cannabidiol loaded microparticles. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 154, 246-258.	2.0	20
56	Global metabolic profile identifies choline kinase alpha as a key regulator of glutathione-dependent antioxidant cell defense in ovarian carcinoma. Oncotarget, 2015, 6, 11216-11230.	0.8	20
57	Impact of COVID-19 in gynecologic oncology: a Nationwide Italian Survey of the SIGO and MITO groups. Journal of Gynecologic Oncology, 2020, 31, e92.	1.0	20
58	c-FLIPL expression defines two ovarian cancer patient subsets and is a prognostic factor of adverse outcome. Endocrine-Related Cancer, 2009, 16, 443-453.	1.6	19
59	Efficiency of T cell triggering by anti-CD3 monoclonal antibodies (mAb) with potential usefulness in bispecific mAb generation. Cancer Immunology, Immunotherapy, 1997, 44, 257-264.	2.0	18
60	miRNA control of apoptotic programs: focus on ovarian cancer. Expert Review of Molecular Diagnostics, 2011, 11, 277-286.	1.5	18
61	Guidance of Signaling Activations by Cadherins and Integrins in Epithelial Ovarian Cancer Cells. International Journal of Molecular Sciences, 2016, 17, 1387.	1.8	18
62	Anti-ovarian carcinoma anti-T3 heteroconjugates or hybrid antibodies induce tumor cell lysis by cytotoxic T-cells. International Journal of Cancer, 1988, 41, 18-21.	2.3	17
63	Targeting of Anti-Tumor Responses with Bispecific Antibodies. Immunobiology, 1992, 185, 390-402.	0.8	17
64	Design, selection and optimization of an anti-TRAIL-R2/anti-CD3 bispecific antibody able to educate T cells to recognize and destroy cancer cells. MAbs, 2018, 10, 1084-1097.	2.6	17
65	Full preclinical validation of the 123I-labeled anti-PSMA antibody fragment ScFvD2B for prostate cancer imaging. Oncotarget, 2017, 8, 10919-10930.	0.8	17
66	Human carcinoma cell lines xenografted in athymic mice: biological and antigenic characteristics of an intraabdominal model. Cancer Immunology, Immunotherapy, 1987, 24, 13-8.	2.0	16
67	Targeting of T lymphocytes against egf-receptor+ tumor cells by bispecific monoclonal antibodies: Requirement of CD3 molecule cross-linking for t-cell activation. International Journal of Cancer, 1993, 55, 931-937.	2.3	15
68	Effect of Pantethine on Ovarian Tumor Progression and Choline Metabolism. Frontiers in Oncology, 2016, 6, 244.	1.3	15
69	Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: predictive value of DNA-PK and phosphorylated ACC. Oncotarget, 2016, 7, 72654-72661.	0.8	15
70	Retargeting of human lymphocytes against human ovarian carcinoma cells by bispecific antibodies: from laboratory to clinic. International Journal of Clinical and Laboratory Research, 1992, 21, 159-164.	1.0	13
71	Anti-CD3/Anti-Epidermal Growth Factor Receptor-Bispecific Antibody Retargeting of Lymphocytes against Human Neoplastic Keratinocytes in an Autologous Organotypic Culture Model. American Journal of Pathology, 2002, 160, 113-122.	1.9	11
72	Effect of radiochemical modification on biodistribution of scFvD2B antibody fragment recognising prostate specific membrane antigen. Immunology Letters, 2015, 168, 105-110.	1.1	11

#	Article	IF	Citations
73	Ascites interferes with the activity of lurbinectedin and trabectedin: Potential role of their binding to alpha 1-acid glycoprotein. Biochemical Pharmacology, 2017, 144, 52-62.	2.0	11
74	Phosphatidylcholine-specific phospholipase C inhibition reduces HER2-overexpression, cell proliferation andin vivotumor growth in a highly tumorigenic ovarian cancer model. Oncotarget, 2017, 8, 55022-55038.	0.8	11
75	Analysis of production, purification, and cytolytic potential of bi-specific antibodies reactive with ovarian-carcinoma-associated antigens and the T-cell antigen CD3. International Journal of Cancer, 1993, 55, 128-136.	2.3	10
76	A critical comparison of three internalization assays applied to the evaluation of a given mAb as a toxin-carrier candidate. Cancer Immunology, Immunotherapy, 1993, 37, 54-60.	2.0	10
77	A Cell-Autonomous Oncosuppressive Role of Human RNASET2 Affecting ECM-Mediated Oncogenic Signaling. Cancers, 2019, 11, 255.	1.7	9
78	Choline kinase alpha impairment overcomes TRAIL resistance in ovarian cancer cells. Journal of Experimental and Clinical Cancer Research, 2021, 40, 5.	3.5	9
79	In vivo Magnetic Resonance Metabolic and Morphofunctional Fingerprints in Experimental Models of Human Ovarian Cancer. Frontiers in Oncology, 2016, 6, 164.	1.3	8
80	Focal Recurrent Copy Number Alterations Characterize Disease Relapse in High Grade Serous Ovarian Cancer Patients with Good Clinical Prognosis: A Pilot Study. Genes, 2019, 10, 678.	1.0	8
81	Ovarian Cancer Translational Activity of the Multicenter Italian Trial in Ovarian Cancer (MITO) Group: Lessons Learned in 10 Years of Experience. Cells, 2020, 9, 903.	1.8	8
82	Development of a new vaccine formulation that enhances the immunogenicity of tumor-associated antigen CaMBr1. Cancer Immunology, Immunotherapy, 2000, 49, 296-304.	2.0	7
83	Production and validation of the pharmacokinetics of a single-chain Fv fragment of the MGR6 antibody for targeting of tumors expressing HER-2. Cancer Immunology, Immunotherapy, 2001, 49, 679-686.	2.0	7
84	A Bispecific Antibody to Link a TRAIL-Based Antitumor Approach to Immunotherapy. Frontiers in Immunology, 2019, 10, 2514.	2.2	7
85	Integration of MRI and MRS approaches to monitor molecular imaging and metabolomic effects of trabectedin on a preclinical ovarian cancer model. NMR in Biomedicine, 2019, 32, e4016.	1.6	7
86	Cytokine Release by Peripheral Blood Lymphocytes Targeted with Bispecific Antibodies, and Its Role in Blocking Tumor Growth. Annals of the New York Academy of Sciences, 1991, 636, 288-294.	1.8	6
87	Bispecific antibodies and retargeted cellular cytotoxicity: novel approaches to cancer therapy. International Journal of Clinical and Laboratory Research, 1992, 22, 17-20.	1.0	6
88	Approaches to implement bispecific antibody treatment of ovarian carcinoma. Cancer Immunology, Immunotherapy, 1997, 45, 187-189.	2.0	6
89	Gynecological Cancers Translational, Research Implementation, and Harmonization: Gynecologic Cancer InterGroup Consensus and Still Open Questions. Cells, 2019, 8, 200.	1.8	6
90	MiR-506: A Multitasker in Suppression of the Epithelial-to-Mesenchymal Transition. RNA & Disease (Houston, Tex), 2014, 1, e447.	1.0	5

#	Article	IF	Citations
91	Prognostic Evidence of the miRNA-Based Ovarian Cancer Signature MiROvaR in Independent Datasets. Cancers, 2021, 13, 1544.	1.7	4
92	Stathmin regulates mutant p53 stability and transcriptional activity in ovarian cancer. EMBO Molecular Medicine, 2014, 6, 295-295.	3.3	3
93	Validation of MiROvaR, a microRNA-based predictor of early relapse in early stage epithelial ovarian cancer as a new strategy to optimise patients' prognostic assessment. European Journal of Cancer, 2022, 161, 55-63.	1.3	3
94	A miRNA signature assessing ovarian cancer prognosis. Oncoscience, 2016, 3, 308-310.	0.9	2
95	Olaparib beyond progression compared with platinum chemotherapy after secondary cytoreductive surgery in patients with recurrent ovarian cancer: phase III randomized, open-label MITO 35b study, a project of the MITO-MANGO groups. International Journal of Gynecological Cancer, 2022, 32, 799-803.	1.2	2
96	Impairment of RAD17 Functions by miR-506-3p as a Novel Synthetic Lethal Approach Targeting DNA Repair Pathways in Ovarian Cancer. Frontiers in Oncology, 0, 12, .	1.3	2
97	miRNA-based signature for predicting epithelial ovarian cancer recurrence. Translational Cancer Research, 2017, 6, S232-S234.	0.4	1
98	The Effect of Human Serum on the Binding Activity of Radiolabelled Monoclonal Antibodies. Tumori, 1987, 73, 547-554.	0.6	0
99	Unidirectional potentiation of binding between two anti-FBP MAbs: Evaluation of involved mechanisms. Journal of Cellular Biochemistry, 1995, 58, 47-55.	1.2	0
100	Aberrant phosphatidylcholine metabolism in human ovarian cancer. Chemistry and Physics of Lipids, 2010, 163, S63.	1.5	0
101	Genomic Landscape of Ovarian Cancer. , 2013, , 295-348.		0